http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. </p><p> Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.criver.com%2F&amp;esheet=54570021&amp;newsitemid=20260715645370&amp;lan=en-US&amp;anchor=ir.criver.com&amp;index=1&amp;md5=c533e4daeaedcf73fd7ee63db60d1f04" shape="rect">ir.criver.com</a>. A replay will be accessible through the same website. </p><p> <b>About Charles River</b> </p><p> Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and http://www.streetinsider.com/Press+Releases/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html Wed, 15 Jul 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Press+Releases/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. </p><p> Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.criver.com%2F&amp;esheet=54570021&amp;newsitemid=20260715645370&amp;lan=en-US&amp;anchor=ir.criver.com&amp;index=1&amp;md5=c533e4daeaedcf73fd7ee63db60d1f04" shape="rect">ir.criver.com</a>. A replay will be accessible through the same website. </p><p> <b>About Charles River</b> </p><p> Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and http://www.streetinsider.com/Press+Releases/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html Wed, 15 Jul 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Business+Wire/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. </p><p> Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.criver.com%2F&amp;esheet=54570021&amp;newsitemid=20260715645370&amp;lan=en-US&amp;anchor=ir.criver.com&amp;index=1&amp;md5=c533e4daeaedcf73fd7ee63db60d1f04" shape="rect">ir.criver.com</a>. A replay will be accessible through the same website. </p><p> <b>About Charles River</b> </p><p> Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and http://www.streetinsider.com/Business+Wire/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html Wed, 15 Jul 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Business+Wire/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2026 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 5th, at 9:00 a.m. ET. </p><p> Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.criver.com%2F&amp;esheet=54570021&amp;newsitemid=20260715645370&amp;lan=en-US&amp;anchor=ir.criver.com&amp;index=1&amp;md5=c533e4daeaedcf73fd7ee63db60d1f04" shape="rect">ir.criver.com</a>. A replay will be accessible through the same website. </p><p> <b>About Charles River</b> </p><p> Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and http://www.streetinsider.com/Business+Wire/Charles+River+Laboratories+Schedules+Second-Quarter+2026+Earnings+Release+and+Conference+Call/26771057.html Wed, 15 Jul 2026 08:00:00 -0400 CRL O.00066481 http://www.streetinsider.com/Corporate+News/Charles+River+to+provide+NGS+services+for+Arovella+cancer+therapy/26760149.html <p>Charles River Laboratories International (NYSE: CRL) announced a collaboration with Arovella Therapeutics to provide Good Manufacturing Practice Next Generation Sequencing (NGS) services for cell characterization in support of Arovella's cancer cell therapy program.</p><p>Under the agreement, Charles River will provide GMP NGS services for cell bank characterization and perform viral safety release testing on clinical batches of ALA-101, Arovella's off-the-shelf CAR-iNKT cell therapy candidate targeting CD19+ B cell lymphomas and leukemias.</p><p>The FDA accepted the use of NGS for viral safety testing of two cell banks that produce reagents used in the ALA-101 manufacturing process as part of a successful Investigational New http://www.streetinsider.com/Corporate+News/Charles+River+to+provide+NGS+services+for+Arovella+cancer+therapy/26760149.html Mon, 13 Jul 2026 08:03:25 -0400 CRL http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Press+Releases/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html <p class="bwalignc"> <i>Collaboration aligns with Charles River’s strategic commitment to building deeper client relationships and accelerating development with alternative methods</i> </p> <p> WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA approved the use of NGS for viral safety testing of two cell banks http://www.streetinsider.com/Business+Wire/Charles+River+Provides+NGS+Services+to+Arovella+Therapeutics%2C+Accelerating+Progress+Toward+Alternative+Cancer+Treatment+Approaches/26759981.html Mon, 13 Jul 2026 08:00:00 -0400 A.06822034 A.17865029 ALA CRL O.00066481 O.00498106 O.00756553 O.20026344 http://www.streetinsider.com/Analyst+PT+Change/Charles+River+Labs+%28CRL%29+PT+Raised+to+%24255+at+Baird/26759732.html Baird analyst Eric Coldwell raised the price target on Charles River Labs (NYSE: CRL) to $255.00 (from $213.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Charles+River+Labs+%28CRL%29+PT+Raised+to+%24255+at+Baird/26759732.html Mon, 13 Jul 2026 07:20:18 -0400 CRL http://www.streetinsider.com/Analyst+PT+Change/Charles+River+Labs+%28CRL%29+PT+Raised+to+%24230+at+Mizuho/26759431.html Mizuho analyst Ann Hynes raised the price target on Charles River Labs (NYSE: CRL) to $230.00 (from $192.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Charles+River+Labs+%28CRL%29+PT+Raised+to+%24230+at+Mizuho/26759431.html Mon, 13 Jul 2026 06:43:35 -0400 CRL http://www.streetinsider.com/Analyst+PT+Change/Charles+River+Labs+%28CRL%29+PT+Raised+to+%24260+at+Morgan+Stanley/26750571.html Morgan Stanley analyst Kallum Titchmarsh raised the price target on Charles River Labs (NYSE: CRL) to $260.00 (from $220.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Charles+River+Labs+%28CRL%29+PT+Raised+to+%24260+at+Morgan+Stanley/26750571.html Thu, 09 Jul 2026 08:15:44 -0400 CRL http://www.streetinsider.com/Trader+Talk/Citi+Adds+Four+Names+to+Catalyst+Call+List+/26743503.html (Updated - July 8, 2026 5:46 AM EDT) <p>Citi Adds Four Names to Catalyst Call List.</p><ul><li>Adds:<ul><li>90-Day <strong>Upside </strong>Catalyst Watch on Intuitive Surgical (NASDAQ: ISRG), Charles River Laboratories (NYSE: CRL), and GE HealthCare (NASDAQ: GEHC).</li><li>90-Day <strong>Downside</strong> Catalyst Watch on Haemonetics (NYSE: HAE)</li></ul></li></ul> http://www.streetinsider.com/Trader+Talk/Citi+Adds+Four+Names+to+Catalyst+Call+List+/26743503.html Wed, 08 Jul 2026 05:46:08 -0400 CRL GEHC HAE ISRG